Dr. Mohamed ElSayed is a Research Fellow at Eli Lilly and Company. In his current role as the Oral Peptide Delivery Platform Leader, Dr. ElSayed has developed and executed an integrated strategy for discovery and development of novel oral peptides as disruptive therapies. He has built from the ground a cross-functional multisite team of talented scientists that delivers Lillys oral peptides portfolio. Prior to joining Lilly Biotechnology Organization, Dr. ElSayed was a tenured professor at the University of Michigan, Ann Arbor, where he established and led the Cellular Engineering and Nano-Therapeutics Laboratory. Dr. ElSayed has +25 years of experience leading teams focusing on drug product development.